Notices
22 February 2016
Echinocandins for antifungal prophylaxis in liver transplant recipients: Advance in the field or variation on a theme?
Christine Koval – 22 February 2016
Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans
Lei Li, Li Che, Kevin M. Tharp, Hyo‐Min Park, Maria G. Pilo, Dan Cao, Antonio Cigliano, Gavinella Latte, Zhong Xu, Silvia Ribback, Frank Dombrowski, Matthias Evert, Gregory J. Gores, Andreas Stahl, Diego F. Calvisi, Xin Chen – 22 February 2016 – Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most prevalent types of primary liver cancer. These malignancies have limited treatment options, resulting in poor patient outcomes. Metabolism reprogramming, including increased de novo lipogenesis, is one of the hallmarks of cancer.
Quality of care metrics in chronic hepatitis B
Jessica Mellinger, Robert J. Fontana – 18 February 2016
Atorvastatin and fluvastatin are associated with dose‐dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES
Tracey G. Simon, Hector Bonilla, Peng Yan, Raymond T. Chung, Adeel A. Butt – 18 February 2016 – Statins are associated with delayed fibrosis progression and a reduced risk of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV). Limited data exist regarding the most effective type and dose of statin in this population. We sought to determine the impact of statin type and dose upon fibrosis progression and HCC in patients with HCV.
The many faces of positive hepatitis B surface antigen
Derek M. Tang, Theo Heller, Christopher Koh – 18 February 2016
Nonalcoholic fatty liver disease and elastography: Incremental advances but work still to be done
William N. Hannah, Stephen A. Harrison – 18 February 2016
Reply
Jospehine Simonetti, Lisa Bulkow, Brian J. McMahon, Chriss Homan, Mary Snowball, Susan Negus, James Williams, Stephen E. Livingston – 18 February 2016
Beta‐blockers in 2016: Still the safest and most useful drugs for portal hypertension?
Gennaro D'Amico, Giuseppe Malizia, Jaime Bosch – 18 February 2016